Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 Receptor Subunit Alpha 5 or GABRA5 Pipeline Review H1 2017
ReportsWeb.com has announced the addition of the “Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 Receptor Subunit Alpha 5 or GABRA5 Pipeline Review H1 2017” this report provides an overview of the Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (
(EMAILWIRE.COM, July 06, 2017 ) Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) - Gamma-aminobutyric acid A receptor, alpha 5 or GABRA5 is a protein encoded by the GABRA5 gene. it , mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Alzheimer's Disease, Autism, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS) , Depression, Ischemic Cerebral Stroke, Ischemic Stroke, Mild Cognitive Impairment, Schizophrenia and Traumatic Brain Injury.
The latest report Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 - Pipeline Review, H1 2017, outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics development with respective active and dormant or discontinued projects.
For more information about this report at http://www.reportsweb.com/gamma-aminobutyric-acid-receptor-subunit-alpha-5-receptor-subunit-alpha-5-or-gabra5-pipeline-review-h1-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5)
- The report reviews Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001858685/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
AgeneBio Inc
F. Hoffmann-La Roche Ltd
Les Laboratoires Servier SAS
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001858685/discount
List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by AgeneBio Inc, H1 2017
Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Pipeline by Les Laboratoires Servier SAS, H1 2017
Dormant Projects, H1 2017
Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001858685/buy/3500
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Alzheimer's Disease, Autism, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS) , Depression, Ischemic Cerebral Stroke, Ischemic Stroke, Mild Cognitive Impairment, Schizophrenia and Traumatic Brain Injury.
The latest report Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 - Pipeline Review, H1 2017, outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics development with respective active and dormant or discontinued projects.
For more information about this report at http://www.reportsweb.com/gamma-aminobutyric-acid-receptor-subunit-alpha-5-receptor-subunit-alpha-5-or-gabra5-pipeline-review-h1-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5)
- The report reviews Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001858685/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA (A) Receptor Subunit Alpha 5 or GABRA5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
AgeneBio Inc
F. Hoffmann-La Roche Ltd
Les Laboratoires Servier SAS
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001858685/discount
List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by AgeneBio Inc, H1 2017
Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Pipeline by Les Laboratoires Servier SAS, H1 2017
Dormant Projects, H1 2017
Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001858685/buy/3500
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results